Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
| Revenue (TTM) | $557.00M |
| Gross Profit (TTM) | $379.10M |
| EBITDA | $-111.90M |
| Operating Margin | -21.40% |
| Return on Equity | -23.50% |
| Return on Assets | -7.65% |
| Revenue/Share (TTM) | $7.45 |
| Book Value | $3.57 |
| Price-to-Book | 1.69 |
| Price-to-Sales (TTM) | 0.99 |
| EV/Revenue | 0.793 |
| EV/EBITDA | -23.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -20.80% |
| Shares Outstanding | $94.45M |
| Float | $85.99M |
| % Insiders | 3.76% |
| % Institutions | 96.92% |
Volatility is currently expanding
New published data shows Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for prostate cancer.
Myriad (MYGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
SALT LAKE CITY, June 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces today the appointment of Raj Jampa as chief technology officer (CTO), effective June 1, 2026. “Raj is a proven technology leader with the vision and execution experience to help scale our business and accelerate technology innovation across the enterprise,” said Sam Raha, Chief Executive Officer, Myriad Genetics.
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.
